Article
Brochure
Executive Resource
Insight Hub
Video
Ext. Publication
Home /
Insights & Resources
Insights & Resources
Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.
- Alternative Investments
- Banking
- Blockchain & Digital Assets
- Construction
- Consumer Products
- Energy Transition
- Financial Services
- Food & Beverage
- General Business
- Government
- Health Care
- Higher Education
- Hospitality & Entertainment
- Industrial Products
- Insurance
- Life Sciences
- Not-for-Profit
- Oil & Gas
- Oilfield Services
- Real Estate
- Renewable Fuels
- Technology
- Transportation & Logistics
- Accounting Advisory
- Artificial Intelligence
- Asset Management Consulting
- Asset Tracing
- Cybersecurity
- Data Privacy
- Digital Transformation
- Energy Compliance
- Executive & Leadership Coaching
- Family Law
- Forensics & Litigation
- Government Consulting
- Health Care Valuation
- IT Advisory
- Risk Advisory
- Sustainability Consulting
- Transaction Advisory
- Trust & Estate
- Valuation
Forensic accountants provide expert testimony and litigation support, translating complex financial data into evidence that attorneys can use.
Forensic accountants value businesses and partnerships in divorce, separating personal from enterprise goodwill to support equitable outcomes.
Forensic accountants trace funds in divorce, clarifying commingling and financial history to support equitable outcomes.
Divorce cases demand financial transparency. Forensic accountants uncover hidden assets and provide evidence that holds up in court.
J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.
Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.
Simplify your decisions during a divorce with the C.L.E.A.R. process. Learn how to organize, prioritize and plan for a confident financial future.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.
With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.
The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.
